Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Forge Announces Visible Gold & Continued Porphyry Mineralization at Alotta Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Citius Oncology Inc CTOR

Healthcare Biotechnology
Citius Oncology, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapies. The Company’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is a targeted immune therapy for relapsed or... see more

Recent & Breaking News (NDAQ:CTOR)

    Citius Oncology Anticipates Commercial Launch of LYMPHIR(TM) in 2025

    PR Newswire 1 day ago

    Citius Oncology Enters into Distribution Services Agreement with Cardinal Health

    PR Newswire 9 days ago

    Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

    PR Newswire May 14, 2025

    Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

    PR Newswire February 14, 2025

    Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

    PR Newswire February 6, 2025

    Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

    PR Newswire January 7, 2025

    Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

    PR Newswire January 6, 2025

    Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

    PR Newswire December 27, 2024

    Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

    PR Newswire December 27, 2024

    Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

    PR Newswire September 5, 2024